Core Scientific, Inc. (CORZ) has caught the attention of investors following a recent “Buy” rating from John Todaro of Needham, issued on March 3, 2026. This rating brings optimism for the stock, especially with a price target suggesting significant upside from its current level of $15.30. Investors may consider this critical juncture as a potential entry point into a company poised for future growth.
Recent Price Action
In recent trading sessions, CORZ has exhibited notable volatility, closing at $15.30, which reflects a 7.22% decline, or $1.19, from prior sessions. The stock’s trading behavior this week has been lively, with a volume of over 26 million shares, well above its average volume of roughly 11.9 million. With a market capitalization of approximately $4.74 billion, CORZ carries a high beta of 6.89, indicative of its susceptibility to fluctuations in broader market movements. The stock remains significantly below its 52-week high of $23.91, while still comfortably above its low of $1.90, highlighting a rollercoaster year shaped by market conditions and investor sentiment.
Short- and Long-Term Performance
Over the past month, CORZ has seen a robust performance, gaining 35.3%. However, a comparative look at longer time frames reveals a more complex picture. The stock is down 3.37% over the last quarter, illustrating a disconnect between short-term gains and recent broader headwinds. Year-to-date, CORZ has still shown a positive return of 25.5%, which may suggest underlying strength amid market volatility. Recent weekly volatility stands at 5.03%, and monthly volatility is at 4.78%, reflecting the stock’s tendency for sharp price movements, which can attract both risk-loving traders and cautious long-term investors alike.
Earnings and Financials
The earnings landscape for Core Scientific presents a noteworthy challenge, as the company reported an earnings per share (EPS) of -$0.46, starkly missing the estimate of -$0.0698 by a staggering 558.93%. This substantial earnings miss, in conjunction with a previous quarter’s EPS of -$0.04—which also fell short of estimates—raises concerns about the company’s earnings predictability and quality. Despite these hurdles, savvy investors will evaluate whether the factors contributing to these losses are short-term issues or reflective of deeper operational challenges.
Analyst and Consensus View
The analyst community remains bullish on CORZ, as evidenced by its perfect score in recent weeks: seven buy ratings with no holds or sells recorded. The average 90-day price target currently sits at $25.21, with forecasts ranging from a conservative $23 to a more ambitious high of $30. This unanimous support for CORZ from analysts indicates a strong consensus on its potential upside, even as the stock navigates its current challenges.
Stock Grading and Fundamental View
Core Scientific’s Stocks Telegraph Grade, standing at 51, reflects a comprehensive evaluation that suggests the company possesses reasonable fundamentals yet exhibits areas needing improvement. This score aligns with its current market positioning, indicating that while technically sound, Core Scientific must address its recent earnings disappointments to harness investor confidence fully.
Conclusion
For investors, Core Scientific (CORZ) offers a potentially lucrative opportunity, particularly for those with a long-term growth mindset willing to weather volatility. While the recent Buy rating from Needham and strong analyst consensus highlight an upside potential, the company’s earnings challenges must not be overlooked. Investors should weigh the risks of market fluctuations and operational inconsistencies against a backdrop of solid growth prospects. With its current attractive valuation and bullish projections from analysts, CORZ remains a stock worth watching for those seeking exposure to the tech-driven financial landscape.